Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 18 of the 39 sources its claims cite were checked for support.
Abstract
In Candida albicans , Upc2 is a zinc-cluster transcription factor that targets genes, including those of the ergosterol biosynthesis pathway. To date, three documented UPC2 gain-of-function (GOF) mutations have been recovered from fluconazole-resistant clinical isolates that contribute to an increase in ERG11 expression and decreased fluconazole susceptibility. In a group of 63 isolates with reduced susceptibility to fluconazole, we found that 47 overexpressed ERG11 by at least 2-fold over the average expression levels in 3 unrelated fluconazole-susceptible strains. Of those 47 isolates, 29 contained a mutation in UPC2 , whereas the remaining 18 isolates did not. Among the isolates containing mutations in UPC2 , we recovered eight distinct mutations resulting in putative single amino acid substitutions: G648D, G648S, A643T, A643V, Y642F, G304R, A646V, and W478C. Seven of these resulted in increased ERG11 expression, increased cellular ergosterol, and decreased susceptibility to fluconazole compared to the results for the wild-type strain. Genome-wide transcriptional analysis was performed for the four strongest Upc2 amino acid substitutions (A643V, G648D, G648S, and Y642F). Genes commonly upregulated by all four mutations included those involved in ergosterol biosynthesis, in oxidoreductase activity, the major facilitator efflux pump encoded by the MDR1 gene, and the uncharacterized ATP binding cassette transporter CDR11 . These findings demonstrate that gain-of-function mutations in UPC2 are more prevalent among clinical isolates than previously thought and make a significant contribution to azole antifungal resistance, but the findings do not account for ERG11 overexpression in all such isolates of C. albicans .
Overview
CoChat Summary
TL;DR
In a collection of azole-resistant *Candida albicans* clinical isolates, *ERG11* overexpression was common, and many such isolates carried gain-of-function mutations in *UPC2*. Seven of eight recovered Upc2 substitutions increased *ERG11* expression, cellular ergosterol, and resistance to fluconazole and other ergosterol biosynthesis inhibitors, but *UPC2* mutations did not explain all *ERG11* overexpression.
Key findings
- Among 63 isolates with reduced fluconazole susceptibility, 47 overexpressed *ERG11* by at least 2-fold; 29 of those 47 had a *UPC2* mutation, while 18 did not.
- Eight distinct putative Upc2 amino acid substitutions were recovered: G648D, G648S, A643T, A643V, Y642F, G304R, A646V, and W478C; seven increased *ERG11* expression, increased cellular ergosterol, and decreased fluconazole susceptibility, whereas G304R did not.
- In constructed strains, homozygous mutant *UPC2* alleles generally produced stronger *ERG11* expression and lower azole susceptibility than heterozygous strains; G648D gave the highest *ERG11* expression.
- Microarray analysis of four strong *UPC2* GOF alleles (A643V, G648D, G648S, Y642F) found 61 commonly upregulated and 5 commonly downregulated genes, including ergosterol biosynthesis genes, oxidoreductase genes, *MDR1*, and *CDR11*.
Methods
- Used 72 unrelated clinical *C. albicans* isolates from the University of Iowa, including oral and nonoral sources; fluconazole resistance was defined as MIC ≥ 16 µg/ml, and *ERG11*, *CDR1*, *CDR2*, and *MDR1* expression was measured by qRT-PCR.
- Sequenced *UPC2* alleles from isolates overexpressing *ERG11*, then constructed *C. albicans* strains expressing mutant *UPC2* alleles alone, as heterozygotes with wild-type *UPC2*, and as homozygotes using the SAT1-flipper system.
- Measured antifungal MICs by modified CLSI broth microdilution and Etest, quantified cellular ergosterol spectrophotometrically, and performed genome-wide transcriptional profiling with Affymetrix *C. albicans* custom expression arrays.
Limitations
- The paper states that it cannot define the clinical implications of fluconazole resistance among nonoral isolates, that *ERG11* expression levels in clinical isolates did not always match those in laboratory strains constructed with the same *UPC2* allele, and that not all *ERG11* overexpression was explained by *UPC2* GOF mutations.
- The paper states that other regulators of ergosterol biosynthesis, *UPC2* promoter mutation, *UPC2* duplication, trans-acting mutations, or aneuploidy such as chromosome 5 duplication/chr5L isochromosome may contribute, and that combinatorial effects of activated *UPC2* with mutant *ERG11* alleles were not explored.
- Evident from the text: most mechanistic work used laboratory-constructed strains rather than the original clinical isolates, so the direct clinical impact of each individual *UPC2* allele remains inferential.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 2 Not valid · 10 Not checked · 90 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In Candida albicans , Upc2 is a zinc-cluster transcription factor that targets genes, including those of the ergosterol biosynthesis pathway.”
- Also stated in: § Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans · boosted
“Alternately, the zinc-cluster transcription factor Upc2 has been shown to regulate the expression of ERG11 and other genes involved in ergosterol biosynthesis (19, 30).”
What the sources say
- Supportedcites [19] 19. MacPherson S, et al. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother. 49 :1745-1752. source
The Results identify C. albicans Upc2p as a member of the zinc-cluster family of transcriptional regulators. The Results and Discussion report its binding to an ERG2 promoter element and its role in regulating ergosterol-biosynthesis genes. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [30] 30. Silver PM, Oliver BG, White TC. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3 :1391-1397. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans · boosted
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As seen with TAC1 or MRR1 mutations, a loss-of-heterozygosity event that results in two GOF alleles, either by a mitotic recombination event between homologous chromosomes or by a loss of a chromosome combined with a duplication of the homologous chromosome, would provide an advantage when challenged with antifungals (2, 22).”
What the sources say
- Not checked — no full text of the sourcecites [2] 2. Coste AT, et al. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172 :2139-2156. source
- Supportedcites [22] 22. Morschhauser J, et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3 :e164. doi:10.1371/journal.ppat.0030164. source
The Discussion states that two mutated MRR1 alleles produce greater drug resistance than one and that this advantage during antimycotic therapy can select for loss of heterozygosity. It also names mitotic recombination and chromosome loss followed by duplication as routes to that loss. This paper supports the MRR1 portion of the sentence; the TAC1 example has a separate citation. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of those isolates that did overexpress MDR1 , even fewer isolates expressed MDR1 to the levels previously observed in azole-resistant isolates (22).”
What the sources say
- Supportedcites [22] 22. Morschhauser J, et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3 :e164. doi:10.1371/journal.ppat.0030164. source
The citation supports the benchmark of MDR1 overexpression in azole-resistant isolates, not the citing authors’ count of how many of their isolates reached it. In the Results section on MRR1 and MDR1 expression (page not provided), the source reports MDR1 overexpression in fluconazole-resistant clinical isolates F5, G5, and 6692 relative to susceptible isolates. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ERG11 is transcriptionally regulated by the zinc cluster transcription factor Upc2.”
What the sources say
- Partly supportedcites [4] 4. Crowley JH, Leak FW, Jr, Shianna KV, Tove S, Parks LW. 1998. A mutation in a purported regulatory gene affects control of sterol uptake in Saccharomyces cerevisiae. J. Bacteriol. 180 :4177-4183. sourceExperimental — accuracy not yet measured
The Abstract identifies UPC2 as a gene encoding a protein with a Zn(II)2Cys6 DNA-binding motif, and the Discussion describes it as a predicted member of that regulatory protein family. Neither passage establishes that Upc2 transcriptionally regulates ERG11; a search for ERG11 found no passage addressing that relationship. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As has been previously observed in UPC2 GOF mutations, aminoacidsubstitutions resulting from activating mutations were localized near the C terminus, where the activation domain of zinc-cluster transcription factors is found (18).”
What the sources say
- Supportedcites [18] 18. MacPherson S, Larochelle M, Turcotte B. 2006. A fungal family of transcriptional regulators: the zinc cluster proteins. Microbiol. Mol. Biol. Rev. 70 :583-604. source
The Introduction states that the activation domain is most often C-terminal and identifies a gain-of-function UPC2 mutation, Gly888Asp, within that domain. It also reports gain-of-function mutations in the activation domains of other zinc-cluster proteins. The paper describes one specific UPC2 mutation, rather than multiple UPC2 substitutions. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
61 more claims
Create a free account to see all 116 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many ERG11 mutations seem to interfere with drug binding and to decrease susceptibility in an additive manner36.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CaUpc2, the primary transcriptional activator of CaERG11 and other ergosterol biosynthetic pathway genes [16].”
From The Candida glabrata Upc2A transcription factor is a global regulator of antifungal drug resistance pathways (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, mutations in this pathway, causing alterations in enzymes activity or drug binding sites, are major factors which are related with azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the ERG11 and ERG3 genes or the UPC2 gene which encodes a transcription factor contribute to azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, gain-of-function mutations in UPC2 often lead to high expression of ERG11 and make a signi fi cant contribution to azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ RESULTS
“From our collection of 72 isolates, 9 were classified as fluconazole susceptible, while the remaining isolates were resistant.”
§ MATERIALS AND METHODS
“| 1-10 | N/A | Azole susceptible | University of Iowa | | 11-72 | N/A | Azole resistant | University of Iowa |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ MATERIALS AND METHODS
“pUPC2-W467C”
§ MATERIALS AND METHODS
“| 25B2D1 | UPC2M4A | UPC2 W478C ::FRT/ UPC2 W478C ::FRT | This study |”
Citations
Cites
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · cited 1×
“albicans by the interplay of several mechanisms of resistance (17, 21, 23, 32).”
BackgroundA rapid and simple method for preparation of RNA from Saccharomyces cerevisiae
Schmitt, M. E., Brown, T. A., & Trumpower, B. L. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.10.3091 · Cited by 1,338
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Klein, R. S., Harris, C. A., Small, C. B., Moll, B., Lesser, M., & Friedland, G. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408093110602 · Cited by 863 · cited 2×
“Candida albicans is an opportunistic fungal pathogen thatcauses mucosal, cutaneous, and systemic infections, including oropharyngeal candidiasis (OPC), the most frequent infection in people with AIDS (9, 13).”
BackgroundSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“Overexpression of the efflux transporter genes CDR1, CDR2, and MDR1 is a common mechanism of drug resistance in this organism (10, 17, 26).”
BackgroundThe SAT1 flipper, an optimized tool for gene disruption in Candida albicans
Reuß, O., Vik, Å., Kolter, R., & Morschhäuser, J. (2004) · Gene · doi:10.1016/j.gene.2004.06.021 · Cited by 742 · cited 4×
“For selection of strains containing the SAT1-flipper cassette (25), nourseothricin (200 g/ ml) was added to YPD agar plates.”
BackgroundMethodInfluentialSelf-citationAneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733 · cited 1×
“ERG11 gene amplification by chromosome 5 duplication or the presence of a chr5L isochromosome is known to contribute to azole resistance (29).”
BackgroundA Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 1×
“As has been previously observed in UPC2 GOF mutations, amino acid substitutions resulting from activating mutations were localized near the C terminus, where the activation domain of zinc-cluster transcription factors is found (18).”
BackgroundAntifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“albicans clinical isolates demonstrated 47 of these isolates overexpressed ERG11 by at least 2-fold (Flowers et al., 2012).”
BackgroundMethodSelf-citationAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“…of C. albicans suggests that CDR1/CDR2 up-regulation is more prevalent than ERG11 or MDR1 up-regulation, with combinations of CDR1/CDR2 up-regulation and ERG11 alterations as the most common (Goldman et al. 2004; Park and Perlin 2005; Coste et al. 2007; Siikala et al. 2010; Flowers et al. 2012).”
BackgroundInfluentialSelf-citationFluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
“It identified several mutations that were associated with increased ERG11 expression as well as increased ergosterol production.(30) This increased production of the azole target dilutes the activity of the fluconazole and results in resistance.”
BackgroundSelf-citationCandidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
“For example, it regulates the expression of CaERG2 and CaERG11 in C. albicans [88].”
BackgroundInfluentialCandida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
“albicans, Upc2, the key transcriptional regulator of ERG11, has also been identified, as gain-of-function mutations in the corresponding gene’s sequence led to a significant increase in ERG11 expression (286).”
BackgroundContribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294
“b Data were previously published by Flowers et al (6).”
MethodSelf-citationThe Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
Zhang, J., Li, L., Lv, Q., Yan, L., Wang, Y., & Jiang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00691 · Cited by 245
“albicans include A643V, G648D, G648S, and Y642F (Dunkel et al., 2008; Flowers et al., 2012).”
BackgroundEvolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“For example, overexpression of the azole target gene ERG11 has not always been associated with point mutations in its UPC2 regulator [86,90,118], suggesting that other regulators may play a role.”
BackgroundCandida albicans Triggers NLRP3-Mediated Pyroptosis in Macrophages
Wellington, M., Koselny, K., Sutterwala, F. S., & Krysan, D. J. (2014) · Eukaryotic Cell · doi:10.1128/ec.00336-13 · Cited by 227
“albicans (37, 44); however, additional work will be required to identify the specific Upc2-regulated molecules or processes that modulate the ability of C.”
BackgroundStructural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
Yang, H., Tong, J., Lee, C. W., Ha, S., Eom, S. H., & Im, Y. J. (2015) · Nature Communications · doi:10.1038/ncomms7129 · Cited by 223
Bhattacharya, S., Esquivel, B. D., & White, T. C. (2018) · mBio · doi:10.1128/mbio.01291-18 · Cited by 210
“In pathogenic fungi, the mechanisms of drug resistance often include overexpression of membrane transporters, including ATP binding cassette transporters (ABC-T) and major facilitator superfamily transporters (MFS-T), which often show increased expression and efflux activities in resistant isolates (15-18).”
BackgroundMutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
“In this organism, the most commonly reported mechanisms of fluconazole resistance include mutations in the gene encoding the target of the triazole antifungals, CaERG11 , and overexpression of either CaERG11 or genes encoding multidrug-efflux pumps such as CaCDR1 , CaCDR2 , and CaMDR1 (12, 15, 28).”
InfluentialSelf-citationMechanisms of Antifungal Properties of Metal Nanoparticles
Slavin, Y. N., & Bach, H. (2022) · Nanomaterials · doi:10.3390/nano12244470 · Cited by 198
“This can arise due to many mechanisms, including gene upregulation [129] for cell wall component synthesis [130] or efflux pump synthesis [131], modification of target site [132], or development of biofilm [133], amongst others.”
BackgroundAntifungals: Mechanism of Action and Drug Resistance
Prasad, R., Shah, A. H., & Rawal, M. K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-25304-6_14 · Cited by 183
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
“Other UPC2 GOF mutations reported from clinical isolates to exhibit azole resistance are listed in Table 2 [100,101,108–110].”
BackgroundA New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02903 · Cited by 166
“Point mutations in the ERG11 gene, which encodes 14-alphademethylase, the target of the azoles, alters drug affinity and in C. albicans at least, also results in ERG11 overexpression via mutations in the transcription factor UPC2 (Flowers et al., 2012).”
BackgroundCandida albicans and Candida glabrata : global priority pathogens
Katsipoulaki, M., Stappers, M. H. T., Malavia-Jones, D., Brunke, S., Hube, B., & Gow, N. A. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-23 · Cited by 180
“Gain-of-function mutations in the ergosterol pathway transcription factor gene UPC2 ( C. albicans )/ UPC2A ( C. glabrata ) lead to overexpression of ERG11 in both species (124, 125).”
BackgroundDrug resistance in eukaryotic microorganisms
Fairlamb, A. H., Gow, N. A. R., Matthews, K. R., & Waters, A. P. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.92 · Cited by 156
“Changes in the levels of three main efflux pumps Cdr1, Cdr2 and Mdr1 and mutations in the genes encoding the Tac1, Upc2, Pdr1 and Mrr1 transcription factors required for efflux pump upregulation, represent major causes of decreased drug sensistivity 192,193 .”
BackgroundMultidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
“The Upc2 transcriptional regulator is a positive modulator of sterol biosynthesis and mutations in this factor lead to pronounced azole resistance (Flowers et al., 2012).”
BackgroundGsaller, F., Hortschansky, P., Furukawa, T., Carr, P. D., Rash, B., Capilla, J., Müller, C., Bracher, F., Bowyer, P., Haas, H., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005775 · Cited by 133
A phosphorylated transcription factor regulates sterol biosynthesis in Fusarium graminearum
Liu, Z., Jian, Y., Chen, Y., Kistler, H. C., He, P., Ma, Z., & Yin, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-09145-6 · Cited by 148
Lv, Q.-Z., Yan, L., & Jiang, Y.-Y. (2016) · Virulence · doi:10.1080/21505594.2016.1188236 · Cited by 133
Molecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128
“In addition, given that ERG11 expression levels are intrinsically low in JEY355, it is not likely that its direct regulator, UPC2, contains GOF mutations that are usually associated with high expression levels (22).”
BackgroundBranco, J., Miranda, I. M., & Rodrigues, A. G. (2023) · Journal of Fungi · doi:10.3390/jof9010080 · Cited by 164
Morschhäuser, J. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5628-4 · Cited by 118
Self-citationCurrent status of antifungal resistance and its impact on clinical practice
Alcazar‐Fuoli, L., & Mellado, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12896 · Cited by 117
“This mechanism has only been reported in clinical isolates of C. albicans resistant to FCZ, with gain-of-function mutations in the transcription factor UPC2 that led to increased expression of ERG11 (Dunkel et al, 2008; Flowers et al, 2012).”
BackgroundMolecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Abnormal Ergosterol Biosynthesis Activates Transcriptional Responses to Antifungal Azoles
Hu, C., Zhou, M., Wang, W., Sun, X., Yarden, O., & Li, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00009 · Cited by 114
“…efflux pumps and Upc2p that regulates ergosterol biosynthesis genes in C. albicans, govern the expression of many azole-responsive genes and confer azole resistance (Coste et al., 2004; Coste et al., 2006; Dunkel et al., 2008; Heilmann et al., 2010; Flowers et al., 2012; Vasicek et al., 2014).”
BackgroundTreatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“albicans ERG11 coding sequence, resulting in reduced drug-to-target affinity, and gain-of-function mutations in the gene encoding transcription factor UPC2 that lead to enhanced ERG11 expression [50].”
BackgroundNishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Self-citationElucidating Drug Resistance in Human Fungal Pathogens
Xie, J. L., Polvi, E. J., Shekhar-Guturja, T., & Cowen, L. E. (2014) · Future Microbiology · doi:10.2217/fmb.14.18 · Cited by 100
Berkow, E. L., Manigaba, K., Parker, J. E., Barker, K. S., Kelly, S. L., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01358-15 · Cited by 95
“This often occurs due to activating mutations in the gene encoding the transcriptional regulator Upc2 (8, 9).”
BackgroundSelf-citationHyphae-specific genes HGC1, ALS3, HWP1, and ECE1 and relevant signaling pathways in Candida albicans
Fan, Y., He, H., Dong, Y., & Pan, H. (2013) · Mycopathologia · doi:10.1007/s11046-013-9684-6 · Cited by 93
“The principle genes [9–31] for C.”
Chang, W., Liu, J., Zhang, M., Shi, H., Zheng, S., Jin, X., Gao, Y., Wang, S., Ji, A., & Lou, H. (2018) · Nature Communications · doi:10.1038/s41467-018-07633-9 · Cited by 91
Lohberger, A., Coste, A. T., & Sanglard, D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00245-13 · Cited by 85
“Given that the occurrence of UPC2 GOF mutations in clinical isolates acquiring azole resistance is not uncommon (68), it is likely that the negative effect of the UPC2 GOF could be corrected by other compensatory mutations to allow propagation under host conditions.”
BackgroundSchillig, R., & Morschhäuser, J. (2013) · Molecular Microbiology · doi:10.1111/mmi.12327 · Cited by 85
“Upc2 regulates the expression of ergosterol biosynthesis genes, and the overexpression of these genes in strains containing activating mutations in Upc2 confers increased fluconazole resistance (Flowers et al., 2012).”
BackgroundSelf-citationWhat do we know about the biology of the emerging fungal pathogen of humans Candida auris?
Bravo Ruiz, G., & Lorenz, A. (2021) · Microbiological Research · doi:10.1016/j.micres.2020.126621 · Cited by 85
Bhattacharya, S., Sobel, J. D., & White, T. C. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01252-16 · Cited by 83
“Recent studies in which efflux pump overexpression in clinical isolates has been documented have used quantitative real-time reverse transcriptase PCR (qRT-PCR) (20).”
MethodDrug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Burrack, L. S., Todd, R. T., Soisangwan, N., Wiederhold, N. P., & Selmecki, A. (2022) · mBio · doi:10.1128/mbio.00842-22 · Cited by 82
Candida albicans targets that potentially synergize with fluconazole
Lu, H., Shrivastava, M., Whiteway, M., & Jiang, Y. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1884641 · Cited by 81
“Upc2 is a global transcriptional factor of the ERG genes (Znaidi et al. 2008; Flowers et al. 2012), and Upc2 Figure 1.”
BackgroundUPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans
Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00221-13 · Cited by 71
“In the presence of fluconazole, the ERG11 gene product, lanosterol demethylase, is inhibited, leading to the accumulation of toxic sterol precursors and the production of alternate sterols, such as lanosterol, eburicol, obtusifoliol, 14 -methyl fecosterol, and 14 -methylergosta-8,24(28)-dien-3 ,6 -diol (21).”
BackgroundMethodInfluentialSelf-citationSanglard, D., & Coste, A. T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02157-15 · Cited by 77
“ERG11 upregulation also can occur via mechanisms that include GOF mutations in transcription factors such as UPC2 (17), thereby decreasing the ability of azoles to inhibit its action.”
BackgroundJin, X., Zhang, M., Lu, J., Duan, X., Chen, J., Liu, Y., Chang, W., & Lou, H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.016 · Cited by 75
Coping with Stress and the Emergence of Multidrug Resistance in Fungi
Shor, E., & Perlin, D. S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004668 · Cited by 71
“Resistance to azoles can also be mediated by mutations in the gene encoding their cellular target—the Erg11 protein, or by mutations in transcriptional regulators of ERG11 that result in Erg1 overexpression [23,24].”
BackgroundRybak, J. M., Sharma, C., Doorley, L. A., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01585-21 · Cited by 69
“has a combinatorial effect on triazole susceptibility (5, 21, 22).”
Self-citationChoi, M. J., Won, E. J., Shin, J. H., Kim, S. H., Lee, W.-G., Kim, M.-N., Lee, K., Shin, M. G., Suh, S. P., Ryang, D. W., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02652-15 · Cited by 68
Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens
Sharma, J., Rosiana, S., Razzaq, I., & Shapiro, R. S. (2019) · Journal of Fungi · doi:10.3390/jof5010017 · Cited by 65
Medically Important Fungi Respond to Azole Drugs: An Update
Zavřel, M., & White, T. C. (2015) · Future Microbiology · doi:10.2217/fmb.15.47 · Cited by 69
Shah, A. H., Singh, A., Dhamgaye, S., Chauhan, N., Vandeputte, P., Suneetha, K. J., Kaur, R., Mukherjee, P. K., Chandra, J., Ghannoum, M. A., et al. (2014) · Biochemical Journal · doi:10.1042/bj20140010 · Cited by 64
Ergosterol Biosynthesis and Regulation Impact the Antifungal Resistance and Virulence of Candida spp
Eliaš, D., Tóth Hervay, N., & Gbelská, Y. (2024) · Stresses · doi:10.3390/stresses4040041 · Cited by 63
“On the contrary, gain-of-function mutations in the CaUPC2 gene lead to increased expression of CaERG11 [70,72] and an increased cellular ergosterol content [72].”
Liu, J., Wang, S., Qin, T., Li, N., Niu, Y., Li, D., Yuan, Y., Geng, H., Li, X., & Liu, D. (2015) · BMC Genomics · doi:10.1186/s12864-015-2043-x · Cited by 63
“Therefore, the strain became more susceptible to drugs [35–37].”
BackgroundKoselny, K., Mutlu, N., Minard, A. Y., Kumar, A., Krysan, D. J., & Wellington, M. (2018) · mBio · doi:10.1128/mbio.01204-18 · Cited by 60
“albicans UPC2 gain-of-function mutants have increased total cellular ergosterol (45) and increased inflammasome activation (11).”
BackgroundUnderstanding the mechanisms of resistance to azole antifungals in Candida species
Li, Y., Hind, C. K., Furner-Pardoe, J., Sutton, J. M., & Rahman, K. M. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf106 · Cited by 77
Fernandes, C. M., & Poeta, M. D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1792288 · Cited by 61
Investigating Antifungal Susceptibility in Candida Species With MALDI-TOF MS-Based Assays
Delavy, M., Santos, A. R. D., Heiman, C. M., & Coste, A. T. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00019 · Cited by 66
“The third mechanism involves a GOF mutation in the TF Upc2, leading to the upregulation of ERG11 expression and the neutralization of the fluconazole action (Flowers et al., 2012).”
BackgroundImpact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection
Levinson, T., Dahan, A., Novikov, A., Paran, Y., Berman, J., & Ben‐Ami, R. (2021) · Mycoses · doi:10.1111/myc.13191 · Cited by 50
Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains
Popp, C., Hampe, I. A. I., Hertlein, T., Ohlsen, K., Rogers, P. D., & Morschhäuser, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00584-17 · Cited by 56
“As ERG11 overexpression is frequently caused by UPC2 mutations (19), we sequenced the UPC2 alleles of isolate F5 and the matched susceptible isolate F2.”
BackgroundSelf-citationDelavy, M., Cerutti, L., Croxatto, A., Prod’hom, G., Sanglard, D., Greub, G., & Coste, A. T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03000 · Cited by 62
Salazar, S. B., Simões, R., Pedro, N. A., Pinheiro, M. J. F., Carvalho, M. F. N. N., & Mira, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6010023 · Cited by 63
“Summary of the mechanisms of resistance registered in azole-resistant Candida isolates, as described in [40-43,45-70,72,76-79,82,85-89,93,94,97,112-129].”
BackgroundErg6 affects membrane composition and virulence of the human fungal pathogen Cryptococcus neoformans
de Oliveira, F. F. M., Paes, H. C., Peconick, L. D. F., Fonseca, F. L., Marina, C. L., Bocca, A. L., Homem-de-Mello, M., Rodrigues, M. L., Albuquerque, P., Nicola, A. M., et al. (2020) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2020.103368 · Cited by 58
Gamaletsou, M. N., Walsh, T. J., & Sipsas, N. V. (2018) · Turkish Journal of Hematology · doi:10.4274/tjh.2018.0007 · Cited by 64
“ERG11 genindeki mutasyonlar, antif-fungal triazollerin etkinliğini azaltarak C-demetilazın protein yapısını değiştirir.”
BackgroundInfluentialNishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
“Sequencing and/or relative quantitation of mRNA expression of known resistance genes revealed that four of these isolates overexpressed CDR1 relative to the CDR1 mRNA levels of fluconazole-susceptible clinical isolates (19).”
BackgroundMethodInfluentialSelf-citationUPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata
Whaley, S. G., Caudle, K. E., Vermitsky, J.-P., Chadwick, S. G., Toner, G., Barker, K. S., Gygax, S. E., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02217-13 · Cited by 52
Self-citationPais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C. (2019) · Microbial Cell · doi:10.15698/mic2019.03.670 · Cited by 51
Branco, J., Silva, A. P., Silva, R. M., Silva-Dias, A., Pina-Vaz, C., Butler, G., Rodrigues, A. G., & Miranda, I. M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-15 · Cited by 49
“glabrata has shown that gain-of87 function mutations in transcription factors, like MRR1, TAC1, UPC2 or PDR1, are 88 involved in the development of azole resistance in these species (12-19).”
BackgroundMorio, F., Pagniez, F., Besse, M., Gay‐Andrieu, F., Miegeville, M., & Pape, P. L. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.07.013 · Cited by 59
Perlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 49
Hampe, I. A. I., Friedman, J., Edgerton, M., & Morschhäuser, J. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006655 · Cited by 52
Self-citationMechanisms of azole antifungal resistance in clinical isolates of Candida tropicalis
Paul, S., Shaw, D., Joshi, H. N., Singh, S., Chakrabarti, A., Rudramurthy, S. M., & Ghosh, A. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269721 · Cited by 54
“Previous studies have demonstrated the role of ERG1 and UPC2 mutations in azole resistance [13, 31, 33, 34].”
BackgroundRocha, M. F. G., Bandeira, S. P., de Alencar, L. P., Melo, L. M., Sales, J. A., Paiva, M. D. A. N., Teixeira, C. E. C., Castelo‐Branco, D. D. S. C. M., Pereira‐Neto, W. D. A., Cordeiro, R. D. A., et al. (2017) · Mycoses · doi:10.1111/myc.12611 · Cited by 51
Bonifácio, B. V., Vila, T. V. M., Masiero, I. F., da Silva, P. B., da Silva, I. C., Lopes, É. D. O., Ramos, M. A. D. S., de Souza, L. P., Vilegas, W., Pavan, F. R., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02642 · Cited by 54
Liu, J., Yuan, Y., Wu, Z. Q., Li, N., Chen, Y., Qin, T., Geng, H., Li, X., & Liu, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117115 · Cited by 42
“The erg11 overexpression in the Upc2 gain-of-function mutants led to strain resistance to azole fungicides [39].”
BackgroundPopp, C., Ramírez-Zavala, B., Schwanfelder, S., Krüger, I., & Morschhäuser, J. (2019) · mBio · doi:10.1128/mbio.02740-18 · Cited by 42
Self-citationMane, A., Vidhate, P., Kusro, C., Waman, V., Saxena, V., Kulkarni‐Kale, U., & Risbud, A. (2016) · Mycoses · doi:10.1111/myc.12439 · Cited by 41
Joshua, I., & Höfken, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040772 · Cited by 40
“Upc2 also positively regulates the expression of MDR1, which encodes a multidrug transporter of the major facilitator family that exports azoles [79,82,85,86].”
BackgroundVu, B. G., Stamnes, M. A., Li, Y., Rogers, P. D., & Moye-Rowley, W. S. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009582 · Cited by 39
Self-citationSpanner, R., Taliadoros, D., Richards, J. K., Rivera-Varas, V. V., Neubauer, J. D., Natwick, M. B., Hamilton, O., Vaghefi, N., Pethybridge, S. J., Secor, G. A., et al. (2021) · Genome Biology and Evolution · doi:10.1093/gbe/evab209 · Cited by 43
Structural basis for activation of fungal sterol receptor Upc2 and azole resistance
Tan, L., Chen, L., Yang, H., Jin, B., Kim, G., & Im, Y. J. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01117-0 · Cited by 38
Rocha, M. F. G., de Alencar, L. P., Paiva, M. A. N., Melo, L. M., Bandeira, S. P., de Ponte, Y. B., Sales, J. A., Guedes, G. M. D. M., Castelo‐Branco, D. D. S. C. M., Bandeira, T. J. P. G., et al. (2016) · Mycoses · doi:10.1111/myc.12457 · Cited by 43
Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance
Doorley, L. A., Rybak, J. M., Berkow, E. L., Zhang, Q. H., Morschhäuser, J., & Rogers, P. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00289-22 · Cited by 40
Self-citationGenomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in Malassezia restricta
Park, M., Cho, Y., Lee, Y. W., & Jung, W. H. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00191 · Cited by 41
“Numerous studies have revealed that overexpression of ERG11 increases the levels of the antifungal target protein and, therefore, causes resistance to azole antifungal drugs (Flowers et al., 2012; Feng et al., 2016, 2017).”
BackgroundVasicek, E. M., Berkow, E. L., Bruno, V. M., Mitchell, A. P., Wiederhold, N. P., Barker, K. S., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00064-14 · Cited by 36
“In order to determine whether Cas5 influences the fluconazole susceptibility of azole-resistant clinical isolates, we constructed cas5 / mutant strains in the background of an azole-resistant clinical isolate (12-99) known to constitutively maintain four of the most common mechanisms of azole resistance: overexpressio…”
BackgroundMethodSelf-citationStevenson, E. M., Gaze, W. H., Gow, N. A. R., Hart, A. J., Schmidt, W., Usher, J., Warris, A., Wilkinson, H., & Murray, A. K. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.918717 · Cited by 42
Resistance to antifungal therapies
Prasad, R., Banerjee, A., & Shah, A. H. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160067 · Cited by 37
Upc2-mediated mechanisms of azole resistance in Candida auris
Li, J., Aubry, L., Brandalise, D., Coste, A. T., Sanglard, D., & Lamoth, F. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03526-23 · Cited by 33
“Previous analyses in C. albicans showed that Upc2 regulates other genes involved in azole resistance, such as drug transporters of the major facilitator superfamily (MFS) or ATP-binding cassette (ABC) family (14, 17).”
BackgroundMethodInfluentialSerratore, N. D., Baker, K. M., Macadlo, L. A., Gress, A. R., Powers, B. L., Atallah, N., Westerhouse, K. M., Hall, M. C., Weake, V. M., & Briggs, S. D. (2018) · Genetics · doi:10.1534/genetics.117.300554 · Cited by 33
Gallo-Ebert, C., Donigan, M., Stroke, I. L., Swanson, R. N., Manners, M. T., Francisco, J., Toner, G., Gallagher, D., Huang, C.-Y., Gygax, S. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01677-13 · Cited by 32
“albicans strains have conserved CaUPC2 gain-of-function mutations that are seen in ScUPC2 alleles conferring resistance (35, 36, 38).”
BackgroundSelf-citationPDR-like ABC systems in pathogenic fungi
Moréno, A., Banerjee, A., Prasad, R., & Falson, P. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2019.09.002 · Cited by 37
Baker, K. M., Hoda, S., Saha, D., Gregor, J. B., Georgescu, L., Serratore, N. D., Zhang, Y., Cheng, L., Lanman, N. A., & Briggs, S. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02250-21 · Cited by 30
Derkacz, D., Bernat, P., & Krasowska, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031631 · Cited by 33
Luna-Tapia, A., Willems, H. M. E., Parker, J. E., Tournu, H., Barker, K. S., Nishimoto, A. T., Rogers, P. D., Kelly, S. L., Peters, B. M., & Palmer, G. E. (2018) · mBio · doi:10.1128/mbio.00225-18 · Cited by 29
“Expression levels of ERG3 were compared to those of ACT1 (normalizing gene) using the ΔCT method as described previously (54).”
MethodSelf-citationAvramovska, O., & Hickman, M. A. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400752 · Cited by 28
Genome sequence of the opportunistic human pathogen Magnusiomyces capitatus
Brejová, B., Lichancová, H., Brázdovič, F., Hegedűsová, E., Jakúbková, M., Hodorová, V., Džugasová, V., Baláž, A., Zeiselová, L., Cillingová, A., et al. (2018) · Current Genetics · doi:10.1007/s00294-018-0904-y · Cited by 28
Gervais, N. C., Bella, A. A. L., Wensing, L. F., Sharma, J., Acquaviva, V., Best, M. A., López, R. O. C., Fogal, M., Uthayakumar, D., Chavez, A., et al. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac301 · Cited by 30
“2021), including the evolution of antifungal drug resistance (Selmecki et al. 2008; Sanglard et al. 2009; Schubert et al. 2011; Flowers et al. 2012; Lohberger et al. 2014; Todd and Selmecki 2020), host colonization (Prieto et al.”
BackgroundPotent Antifungal Synergy of Phthalazinone and Isoquinolones with Azoles Against Candida albicans
Mood, A. D., Premachandra, I. D. U. A., Hiew, S. C., Wang, F., Scott, K. A., Oldenhuis, N. J., Liu, H., & Vranken, D. L. V. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00355 · Cited by 31
Orie, N. N., Warren, A. R., Basaric, J., Lau‐Cam, C. A., Pįętka-Ottlik, M., Młochowski, J., & Billack, B. (2017) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21892 · Cited by 28
Metadata
- Authors
- Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D.
- Affiliations
- University of Tennessee Health Science Center (US)
- Medical Diagnostic Laboratories (United States) (US)
- University of Würzburg (DE)
- ORCID
- Venue
- Eukaryotic Cell
- Publisher
- American Society for Microbiology
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 1289-1299
- ISSN
- 1535-9778 (ISSN-L)
- 1535-9786
- PMC
- PMC3485914
- OpenAlex
- W2169755129
- Cited by
- 239
- References
- 32
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 25 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 11 · 2017: 20 · 2016: 9 · 2015: 14 · 2014: 16 · 2013: 11
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Eukaryotic Cell (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, UPC2, ERG11, fluconazole resistance, azole resistance, gain-of-function mutations, zinc cluster transcription factors, ergosterol biosynthesis, transcriptional regulation, clinical isolates, antifungal resistance
- MeSH terms
- Antifungal Agents, Candida albicans, Cytochrome P-450 Enzyme System, Ergosterol, Fungal Proteins, Transcription Factors, Transcription, Genetic, Fluconazole, Up-Regulation, Genome, Fungal, Mutation, Missense, ATP Binding Cassette Transporter, Subfamily B, Member 1, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.